Patents by Inventor Songmao Zheng

Songmao Zheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20240117000
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 11, 2024
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF
    Publication number: 20230322888
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: June 9, 2023
    Publication date: October 12, 2023
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 11780900
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 10, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Yue-Mei Zhang, Raul Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof
    Patent number: 11713345
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: August 1, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Shannon Mullican, Matthew M. Rankin, Xiefan Lin-Schmidt, Chichi Huang, Jennifer Furman, Songmao Zheng, Shamina Rangwala, Serena Nelson
  • GDF15 ANALOGS AND METHODS FOR USE IN DECREASING BODY WEIGHT AND/OR REDUCING FOOD INTAKE
    Publication number: 20220315633
    Abstract: The present invention is related to the fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein which function as GDF15 agonists. These GDF15 agonists may be useful in the treatment of obesity, reduction of body weight, decrease in food intake, or decrease of appetite.
    Type: Application
    Filed: November 19, 2019
    Publication date: October 6, 2022
    Inventors: Holly KIMKO, Robert HERMANN, Elisa FABBRINI, Vedrana STOJANOVIC-SUSULIC, Paul ROTHENBERG, Songmao ZHENG
  • GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF
    Publication number: 20220089669
    Abstract: Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.
    Type: Application
    Filed: October 22, 2019
    Publication date: March 24, 2022
    Inventors: Shannon MULLICAN, Matthew M. RANKIN, Xiefan LIN-SCHMIDT, Chichi HUANG, Jennifer FURMAN, Songmao ZHENG, Shamina RANGWALA, Serena NELSON
  • Method for treating pre-type 1 diabetes in a human subject
    Patent number: 11124565
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 21, 2021
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Joseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20210253661
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 10875902
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yue-Mei Zhang, Raul C. Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES
    Publication number: 20190375836
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
    Type: Application
    Filed: August 14, 2019
    Publication date: December 12, 2019
    Applicant: Janssen Biotech, Inc.
    Inventors: Joseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka
  • Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
    Patent number: 10465003
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: November 5, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Joseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20190330296
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 31, 2019
    Inventors: Yue-Mei ZHANG, Raul C. CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES
    Publication number: 20190092849
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
    Type: Application
    Filed: February 2, 2017
    Publication date: March 28, 2019
    Applicant: Janssen Biotech, Inc.
    Inventors: Joseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka
  • ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES
    Publication number: 20170247444
    Abstract: The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D).
    Type: Application
    Filed: February 1, 2017
    Publication date: August 31, 2017
    Applicant: Janssen Biotech, Inc.
    Inventors: Joseph Hedrick, Elizabeth C. Hsia, Paul Imm, Jocelyn Leu, Bethany Paxson, Mark Rigby, Songmao Zheng, Ramineh Zoka